Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
12.89 AUD +0.23% Intraday chart for Telix Pharmaceuticals Limited -2.86% +27.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent CI
Telix Pharmaceuticals Appoints Group COO; Shares Down 4% MT
Telix Pharmaceuticals to Buy Canadian Radioisotope Production Firm ARTMS MT
Telix Pharmaceuticals Limited signed an agreement to acquire ARTMS, INC. for approximately $84 million. CI
Telix Pharmaceuticals Jumps 7% on IsoTherapeutics Group Acquisition Deal MT
Telix Pharmaceuticals Limited entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million. CI
Transcript : Telix Pharmaceuticals Limited, 2023 Earnings Call, Feb 23, 2024
Telix Pharmaceuticals Posts 214% Surge in FY23 Revenue; Returns to Profit MT
Telix Pharmaceuticals Limited Provides Earnings Guidance for Full Year Revenue 2024 CI
Telix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Telix Pharmaceuticals to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform MT
Australia shares led higher by Financials; US inflation in focus RE
Transcript : Telix Pharmaceuticals Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:00 PM
Telix Pharmaceuticals Limited Announces Unaudited Revenue Results for the Fourth Quarter and Full Fiscal Year 2023 CI
Australia's Telix Pharmaceuticals jumps on potential US listing RE
Telix Pharmaceuticals Mulls US IPO MT
Telix Pharmaceuticals Appoints Group Medical Chief MT
Telix Pharmaceuticals Limited Announces Executive Changes CI
Telix Pharmaceuticals Files Biologics License Application with US FDA for Cancer Imaging Agent MT
Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx for Imaging of Kidney Cancer CI
Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent CI
Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS CI
Transcript : Telix Pharmaceuticals Limited - Special Call
Telix Pharmaceuticals to Acquire QSAM Biosciences, CycloSam Lead Therapy MT
Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million. CI
Chart Telix Pharmaceuticals Limited
More charts
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. The Company is developing a portfolio of clinical-stage products that focuses to address the unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). The Company’s lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases. The Company also owns SENSEI radio-guided surgery business.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
12.86 AUD
Average target price
14.88 AUD
Spread / Average Target
+15.69%
Consensus
  1. Stock
  2. Equities
  3. Stock Telix Pharmaceuticals Limited - Australian S.E.
  4. News Telix Pharmaceuticals Limited
  5. Telix Pharmaceuticals : Recruiting Patients for Phase 3 Study of Renal Cancer Imaging Drug